The last ten years have seen a notable increase in balloon pulmonary angioplasty safety.

Published Date: 23 Apr 2023

The treatment of chronic thromboembolic pulmonary hypertension with balloon pulmonary angioplasty has an evolving safety profile over the years, from 2013 to 2022, as revealed by an analysis of more than two dozen studies.

Read Full News

Latest News

Q4 2025 Recap: Pulmonology News and Updates

Q4 2025 Recap: Pulmonology News and Updates

Pulmonology in 2025: Year in Review

Pulmonology in 2025: Year in Review

Asthma in 2025: Year in Review

Asthma in 2025: Year in Review

COPD in 2025: Year in Review

COPD in 2025: Year in Review

Characterizing COPD - Lung Cancer Patients, with Joseph Friedberg, MD Joseph Friedberg, MD, Kevin Kunzmann

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Todays Updates

Claims Study Highlights Persistence and Reasons for Fenfluramine Use in Lennox-Gastaut Syndrome Marco Meglio

An AES study revealed the real-world persistence of fenfluramine in treating Lennox-Gastaut syndrome, highlighting patient demographics and treatment trends.

Fenfluramine’s Safety Profile Consistent in Long-Term Extension Dravet and Lennox-Gastaut Syndrome Studies Isabella Ciccone, MPH

Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.

Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms

Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Young Adults With Glomerular Disease May Require Distinct Care

Young Adults With Glomerular Disease May Require Distinct Care

Q4 2025 Recap: Nephrology News and Updates

Q4 2025 Recap: Nephrology News and Updates

Todays Updates

Claims Study Highlights Persistence and Reasons for Fenfluramine Use in Lennox-Gastaut Syndrome Marco Meglio

An AES study revealed the real-world persistence of fenfluramine in treating Lennox-Gastaut syndrome, highlighting patient demographics and treatment trends.

Fenfluramine’s Safety Profile Consistent in Long-Term Extension Dravet and Lennox-Gastaut Syndrome Studies Isabella Ciccone, MPH

Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.

Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms

Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Young Adults With Glomerular Disease May Require Distinct Care

Young Adults With Glomerular Disease May Require Distinct Care

Q4 2025 Recap: Nephrology News and Updates

Q4 2025 Recap: Nephrology News and Updates

Latest News

Q4 2025 Recap: Pulmonology News and Updates

Pulmonology in 2025: Year in Review

Asthma in 2025: Year in Review

COPD in 2025: Year in Review

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

News All Time

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Achieving Clinical Remission in Asthma Care, With Linda Rogers, MD Linda Rogers, MD

Roger discusses how new therapies are transforming asthma treatment, enabling potential clinical remission.

Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management

Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD Sara Assaf, MD

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Lungcast: Resilience and Sustainability: Preparing Healthcare for the Future with Elizabeth Cerceo, MD Albert Rizzo, MD, Elizabeth Cerceo, MD

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

Long-Term Data Support New Zopapogene Imadenovec Approval for RRP Victoria Johnson

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Nerandomilast Approval Breaks Decade-Long Dry Spell for IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

Mucoactives Found to Have Little Benefit for Bronchiectasis Victoria Johnson

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

FDA Accepts NDA for Chiesi’s Single Inhaler Triple Therapy for Asthma Victoria Johnson

The therapy is currently approved in almost 50 countries under the name Trimbow.

FDA Approval Adds Tezepelumab to CRSwNP Treatment Landscape Victoria Johnson

Tezepelumab is the first TSLP-targeting biologic to be approved for chronic rhinosinusitis with nasal poylps.

Redefining Severe Airway Disease Care: Clinicians Weigh In on Biologics and Barriers Victoria Johnson

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

4 Trials That May Change Pulmonary Embolism, with Parth Rali, MD Parth Rali, MD

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

Sleep Apnea Significantly Impacts Mortality Benefit of GLP-1s Kevin Kunzmann

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

Dupilumab, Tezepelumab Provide Consistent Real-World Severe Asthma Outcomes Kevin Kunzmann

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

Recommended News For You

younger kidney cancer survivors are more susceptible to heart problems.

Make the Diagnosis: Can You Explain Her Rash and Conjunctival Injection?

Un nou sistem de endoscopică imaging are capacitatea de a detecta mai mulți fluorescent tracers.

Q&A: Odds of surviving cancer drop drastically when credit score dips

The Higher the Disability Burden From Disease, the Higher the Suicide Risk

Clinical trial sees dramatic results using radiation to treat breast cancer

Childhood cancer survivors face new health problems later in life, study shows

Recommended Articles For You

Cutting-Edge Cancer Treatments: Innovations and Outcomes in Non-Hodgkin Lymphoma 

Demystifying the Mentzer Index: Understanding Its Importance in Inventory Management  

Omentum Cancer: Causes, Symptoms, and Treatment Options 

From Muscle Soreness to Improved Endurance: The Benefits of Monitoring Lactic Acid Levels  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Life quality after childhood cancer is quantifiable thanks to outcome indicators.

2.

"We Caught It Early": Advantage or Disadvantage?

3.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

4.

A protein with new anticancer activity has been identified

5.

Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients

1.

How HLH is Revolutionizing Healthcare

2.

Boosting Checkpoint Immunotherapy in Hodgkin Lymphoma with JAK Inhibition: Advances & Insights

3.

Neuroendocrine Tumors: Mechanisms of Mortality, Associated Conditions

4.

Seeing the Difference: Using Ultrasound to Distinguish Fibroadenoma from Cancer

5.

Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men

2.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

4.

Navigating the Complexities of Ph Negative ALL - Part X

5.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot